Abstract
Comorbidities are an increasing global health challenge. Accumulating evidence suggests overlapping genetic architectures underlying comorbid complex human traits and disorders. The bivariate causal mixture model (MiXeR) can quantify the polygenic overlap between complex phenotypes beyond global genetic correlation. Still, the pattern of genetic overlap between three distinct phenotypes, which is important to better characterize multimorbidities, has previously not been possible to quantify. Here, we present and validate the trivariate MiXeR tool, which disentangles the pattern of genetic overlap between three phenotypes using summary statistics from genome-wide association studies (GWAS). Our simulations show that the trivariate MiXeR can reliably reconstruct different patterns of genetic overlap. We further demonstrate how the tool can be used to estimate the proportions of genetic overlap between three phenotypes using real GWAS data, providing examples of complex patterns of genetic overlap between diverse human traits and diseases that could not be deduced from bivariate analyses. This contributes to a better understanding of the etiology of complex phenotypes and the nature of their relationship, which may aid in dissecting comorbidity patterns and their biological underpinnings.
Availability and implementation The trivariate MiXeR tool and auxiliary scripts, including source code, documentation and examples of use are available at https://github.com/precimed/mix3r
Competing Interest Statement
Srdjan Djurovic has received speaker's Honoria from Lundbeck. Anders M. Dale is a Founder of and holds equity in CorTechs Labs, Inc, and serves on its Scientific Advisory Board. He is also a member of the Scientific Advisory Board of Human Longevity, Inc. (HLI), and the Mohn Medical Imaging and Visualization Centre in Bergen, Norway. He receives funding through a research agreement with General Electric Healthcare (GEHC). The terms of these arrangements have been reviewed and approved by the University of California, San Diego in accordance with its conflict-of-interest policies. Ole A. Andreassen has received speaker fees from Lundbeck, Janssen, Otsuka, and Sunovion and is a consultant to Cortechs.ai and Precision Health AS.
Funding Statement
This work was supported by the Research Council of Norway (grants: 223273, 326813, 273291, 273446, 334920, 324499, 324252, 223273, 300309 and 248778). The European Economic Area and Norway Grants (grants: EEA-RO-NO-2018-0535 and EEA-RO-NO-2018-0573). European Union's Horizon 2020 Research and Innovation Programme (grants: 847776, 801133 and 964874). National Institutes of Health: U24DA041123, U24DA055330, 5R01MH124839-02 and R01MH123724-01. South-Eastern Norway Regional Health Authority (grant 2022073). KG Jebsen Stiftelsen, The South-East Norway Regional Health Authority (grant 2022-087).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The individual-level genotyping data for the current study were obtained from UK Biobank under accession number 27412. All researchers who wish to access this resource must register with UK Biobank by completing the registration form in the Access Management System. GWAS summary statistics data used in this study are publicly available and corresponding links are provided in the manuscript.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present work are contained in the manuscript.
